ABSTRACT GUIDELINES

Call For Abstract

You are invited to submit abstracts for the Sixth MENACTRIMS Congress which will take place from Friday, December 10 to Saturday, December 11, 2021 both physically and virtually at the Intercontinental Hotel, Dubai, United Arab Emirates.

Depending on the number of submitted abstracts and their quality, the abstracts will be selected for either live/on demand oral or for poster presentation. All accepted abstracts will be displayed on the in the virtual website of the congress. Review topics will not be accepted.

This year following the COVID-19 guidelines we are only calling in abstracts for ePosters there will not be physical posters present. Abstracts submissions are possible until October 28, 2021 (18:00 Dubai time +4 GMT). Abstracts can be re-edited and modified until the submission deadline. Any abstract received after the deadline will not be accepted. Upon completion of evaluation an ‘Accepted’ or ‘Rejected’ email will be sent to each application submitted. The result of the evaluation will be sent approximately 14 days after deadline submission.

Abstract Categories

  • Recent Advances in MS Therapy
  • MS Pathology
  • Immunology of MS
  • Epidemiology of MS
  • MS Diagnosis
  • Update on Secondary Progressive MS
  • Neuromyelitis Optica
  • Pediatric MS
  • MRI in MS

Abstract Guidelines

Language:

  • All submitted abstracts must be in English

Author(s):

  • The content of the abstract is solely the responsibility of the author. The original abstract is displayed exactly as provided. During submission, it must clearly indicate the name of the presenting author, who will be considered the contact person for all correspondence connected with the submitted abstract.
  • All submitted abstracts need to have the names and surnames of all co-authors, along with their positions in their affiliated institutions.
  • The presenting author can be any of the listed authors

Length:

  • Poster submissions need to be limited to 500 words.

Title:

  • An abstract must have a short, specific title (no abbreviations) that clearly indicates the nature of the investigation. It is encouraged that the title is set so as to attract the audience and to hint to the conclusion of the investigation.

Content:

  • A well-written abstract typically has the following identified sections:
    1. Background/objectives: a brief introduction, which states the problem that you are addressing as well as some background information on the issue. The introduction of the abstract should include a very brief background 1-2 statements followed by the objectives of the investigation.
    2. Design and methods: the methodologies, number of test subjects and scientific approach used to conduct the research.
    3. Results: it is expected that authors present data that support their conclusion. Tables and graphs should include explanatory captions.
    4. Conclusions: further areas of research and overall conclusion of the research
    5. Citation: a reference list and acknowledgements, if applicable. A maximum of two tables/graphs/images can be included.

Co-Author Approval

The submitting author must verify that all co-authors have read and approved the submission of the abstract.

Submit your Abstract

Submit Now

Virtual ePosters

Virtual delegates can also submit their abstracts regardless if they are physically present or not. The MENACTRIMS 2021 Congress will provide an ePosters section on their LIVE website available from December 5, 2021.

Please note ePosters are not online poster presentations. ePosters will be placed on the virtual MENACTRIMS 2021 Congress website wherein the main author’s contact will be placed on their dedicated ePoster page in the case virtual delegates would like to contact them. Moreover, ePosters pages will contain the submitted abstract along with the design ePoster that accepted abstract authors will need to submit using the MENACTRIMS 2021 Congress abstract template.

Please download the template featured below.

Download Template

Acceptance & Rejection

The reviewers will judge the abstracts according to the scientific or clinical value, relevance to the conference, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.

Upon completion of the evaluation of submitted abstracts, an ‘Accepted’ or ‘Rejected’ email will be sent to authors. Abstract acceptance will be in poster presentation. The scientific committee will select few abstracts for short oral presentation during the meeting. Upon acceptance of an author’s submission, the following instructions below are applicable:

  • The presenting author of the presentation should confirm their attendance upon receiving the acceptance email within one week.
  • The availability of any sort of grant for registration, travel and/or accommodation will be mentioned in the acceptance email, without any guarantees at the abstract submission stage.
  • Accepted authors will receive one complimentary registration pass that will be assigned and sent up to 10 days prior to the conference
  • Authors who confirm presence will receive a free communication code based on their category of submission up to 10 days before the conference.
  • If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the abstract helpdesk at science@medgress.com no later than November 5, 2021
  • Virtual authors: are to submit the electronic version of the abstract in PPT format at least 10 days prior to the conference.
  • Failure to provide the ePoster on time will not expose the abstract on the LIVE conference website of the MENACTRIMS 2021 Congress.

Disclosure

It is the intent of the conference to provide high quality sessions focused on educational content that is free from commercial influence or bias.

A disclosure form identifying commercial relationships or conflict of interest for all co-authors must be completed by the submitting author, if their abstract has been accepted for publication. The submitting author signs and verifies disclosure on behalf of all co-authors. Disclosure information for accepted abstracts will be made available to the conference attendees.